ORION OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.85 EUR | +1.30% |
|
+10.65% | -8.71% |
| 26/04 | Orion Corporation Announces Appointments to Nomination Committee | CI |
| 25/04 | Transcript : Orion Oyj, Q1 2024 Earnings Call, Apr 25, 2024 |
| Sales 2024 * | 1.35B 1.45B 121B | Sales 2025 * | 1.45B 1.55B 129B | Capitalization | 5.04B 5.39B 450B |
|---|---|---|---|---|---|
| Net income 2024 * | 254M 272M 22.65B | Net income 2025 * | 249M 266M 22.21B | EV / Sales 2024 * | 3.73 x |
| Net Debt 2024 * | 4.12M 4.41M 367M | Net cash position 2025 * | 5.14M 5.5M 459M | EV / Sales 2025 * | 3.48 x |
| P/E ratio 2024 * |
19.8
x | P/E ratio 2025 * |
20.2
x | Employees | 3,632 |
| Yield 2024 * |
4.6% | Yield 2025 * |
4.77% | Free-Float | 88.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Orion Oyj
More press releases
More news
| 1 day | +1.30% | ||
| 1 week | +10.65% | ||
| Current month | +3.70% | ||
| 1 month | +4.12% | ||
| 3 months | -18.02% | ||
| 6 months | -1.62% | ||
| Current year | -8.71% |
1 week
32.25
36.12
1 month
31.8636.12
Current year
31.8645.29
1 year
31.8645.29
3 years
31.8655.16
5 years
28.1955.16
10 years
21.4458.50
| Managers | Title | Age | Since |
|---|---|---|---|
Liisa Hurme
CEO | Chief Executive Officer | 57 | 01/99/01 |
| Director of Finance/CFO | 63 | 01/01/01 | |
| Chief Operating Officer | - | 01/16/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 25/21/25 | |
| Director/Board Member | 61 | 22/17/22 | |
| Director/Board Member | 54 | 23/22/23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.96% | 1,331 M€ | +7.08% | ||
| 2.87% | 460 M€ | +1.47% | ||
| 0.35% | 1,120 M€ | +0.40% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 35.85 | +1.30% | 553,435 |
| 25/24/25 | 35.39 | +6.92% | 804,108 |
| 24/24/24 | 33.1 | -0.06% | 312,458 |
| 23/24/23 | 33.12 | +0.36% | 201,846 |
| 22/24/22 | 33 | +1.85% | 234,335 |
Delayed Quote Nasdaq Helsinki, April 26, 2024 at 08:59 pm IST
More quotes
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
35.85
EUR
Average target price
39.2
EUR
Spread / Average Target
+9.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.71% | 5.38B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ORNBV Stock
